JP2002508334A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508334A5
JP2002508334A5 JP2000538716A JP2000538716A JP2002508334A5 JP 2002508334 A5 JP2002508334 A5 JP 2002508334A5 JP 2000538716 A JP2000538716 A JP 2000538716A JP 2000538716 A JP2000538716 A JP 2000538716A JP 2002508334 A5 JP2002508334 A5 JP 2002508334A5
Authority
JP
Japan
Prior art keywords
composition
microparticles
poly
selected antigen
lactide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000538716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508334A (ja
JP4918188B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/001656 external-priority patent/WO1999030737A1/en
Publication of JP2002508334A publication Critical patent/JP2002508334A/ja
Publication of JP2002508334A5 publication Critical patent/JP2002508334A5/ja
Application granted granted Critical
Publication of JP4918188B2 publication Critical patent/JP4918188B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000538716A 1997-12-16 1998-01-29 サブミクロンの水中油型エマルジョンと合わせた微粒子の使用 Expired - Fee Related JP4918188B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6972497P 1997-12-16 1997-12-16
US60/069,724 1997-12-16
PCT/US1998/001656 WO1999030737A1 (en) 1997-12-16 1998-01-29 Use of microparticles combined with submicron oil-in-water emulsions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007292637A Division JP2008050374A (ja) 1997-12-16 2007-11-09 サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
JP2011250804A Division JP2012036223A (ja) 1997-12-16 2011-11-16 サブミクロンの水中油型エマルジョンと合わせた微粒子の使用

Publications (3)

Publication Number Publication Date
JP2002508334A JP2002508334A (ja) 2002-03-19
JP2002508334A5 true JP2002508334A5 (cg-RX-API-DMAC7.html) 2012-01-26
JP4918188B2 JP4918188B2 (ja) 2012-04-18

Family

ID=22090819

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000538716A Expired - Fee Related JP4918188B2 (ja) 1997-12-16 1998-01-29 サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
JP2007292637A Withdrawn JP2008050374A (ja) 1997-12-16 2007-11-09 サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
JP2011250804A Withdrawn JP2012036223A (ja) 1997-12-16 2011-11-16 サブミクロンの水中油型エマルジョンと合わせた微粒子の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007292637A Withdrawn JP2008050374A (ja) 1997-12-16 2007-11-09 サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
JP2011250804A Withdrawn JP2012036223A (ja) 1997-12-16 2011-11-16 サブミクロンの水中油型エマルジョンと合わせた微粒子の使用

Country Status (11)

Country Link
US (4) US6086901A (cg-RX-API-DMAC7.html)
EP (1) EP1042001B1 (cg-RX-API-DMAC7.html)
JP (3) JP4918188B2 (cg-RX-API-DMAC7.html)
AT (1) ATE215385T1 (cg-RX-API-DMAC7.html)
AU (1) AU6253898A (cg-RX-API-DMAC7.html)
CA (1) CA2314934C (cg-RX-API-DMAC7.html)
DE (1) DE69804671T2 (cg-RX-API-DMAC7.html)
DK (1) DK1042001T3 (cg-RX-API-DMAC7.html)
ES (1) ES2175668T3 (cg-RX-API-DMAC7.html)
PT (1) PT1042001E (cg-RX-API-DMAC7.html)
WO (1) WO1999030737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
CA2156718A1 (en) 1993-12-23 1995-06-29 Bruno Gander Immunological response potentiation process
EP2298900A1 (en) * 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
ES2195317T3 (es) * 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
WO2000050006A2 (en) * 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
ATE454901T1 (de) * 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
CA2389613A1 (en) * 1999-11-19 2001-05-25 Zycos Inc. Continuous-flow method for preparing microparticles
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030138453A1 (en) * 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
WO2002026212A2 (en) 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
ES2399386T3 (es) * 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003055323A1 (en) * 2001-12-27 2003-07-10 Genesis Group Inc. Seal oil based lipid emulsions and uses thereof
ES2339762T3 (es) * 2002-01-14 2010-05-25 Novartis Vaccines And Diagnostics, Inc. Vacuna contra el vih y procedimiento de uso.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
US7056901B2 (en) * 2002-03-29 2006-06-06 The Regents Of The University Of California Microgel particles for the delivery of bioactive materials
RU2214278C1 (ru) * 2002-05-27 2003-10-20 Закрытое Акционерное Общество "Нита-Фарм" Адьювант для биопрепаратов
US20040013688A1 (en) * 2002-07-03 2004-01-22 Cambridge Scientific, Inc. Vaccines to induce mucosal immunity
AU2003254792A1 (en) * 2002-08-02 2004-02-23 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
US7884083B2 (en) * 2002-08-12 2011-02-08 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
WO2004032860A2 (en) * 2002-10-07 2004-04-22 Chiron Corporation Hiv vaccine formulations
US7955260B2 (en) * 2002-10-18 2011-06-07 Datacquire, Inc. Method for rating severity of psoriasis
EP2263687B1 (en) * 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
US20050191358A1 (en) * 2003-01-14 2005-09-01 Derek O' Hagan Microparticles with adsorbed polynucleotide-containing species
RU2541809C2 (ru) * 2003-04-04 2015-02-20 Зоетис Пи ЛЛК Микрофлюидизированные эмульсии "масло в воде" и композиции вакцины
WO2004091491A2 (en) * 2003-04-10 2004-10-28 Transform Pharmaceuticals, Inc. Profiling conformational variants, antibody compositions and methods of using the same
WO2005003180A2 (en) * 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
WO2004096136A2 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
US7208395B2 (en) * 2003-06-26 2007-04-24 Semiconductor Energy Laboratory Co., Ltd. Laser irradiation apparatus, laser irradiation method, and method for manufacturing semiconductor device
US20050053667A1 (en) * 2003-07-09 2005-03-10 Darrell Irvine Programmed immune responses using a vaccination node
AU2004259208B2 (en) * 2003-07-15 2011-04-28 Evonik Corporation Method for the preparation of controlled release formulations
AU2004259209A1 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
AU2005334819B2 (en) * 2004-11-15 2011-11-24 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
MX2009004866A (es) * 2006-11-03 2009-05-19 Schering Plough Ltd Vacuna para enfermedad de lyme canina.
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
ES2588705T3 (es) * 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
AU2008331800A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
AU2008335457B2 (en) * 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
US20110151015A1 (en) * 2008-03-04 2011-06-23 Liquikia Technologies, Inc. Immunomodulator particles and methods of treating
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
NZ591768A (en) * 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
JP2012510289A (ja) 2008-12-03 2012-05-10 プロティア ワクチン テクノロジーズ リミテッド グルタミルtRNA合成酵素(GtS)フラグメント
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20110293690A1 (en) * 2010-05-27 2011-12-01 Tyco Healthcare Group Lp Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
US20130004640A1 (en) * 2011-07-01 2013-01-03 Pepsico, Inc. Complex coacervates, methods and food products
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
IN2014CN02581A (cg-RX-API-DMAC7.html) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2702278T3 (es) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10426828B2 (en) 2014-04-03 2019-10-01 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
WO1992000081A1 (en) * 1990-06-29 1992-01-09 Chiron Corporation Vaccine compositions containing liposomes
US5928865A (en) * 1992-03-02 1999-07-27 Chiron S.P.A. Compositions comprising isolated Helicobacter pylori CagI polynucleotides and method of preparation thereof
EP0724432B1 (en) * 1993-10-22 2002-09-18 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
WO1995033835A1 (en) * 1994-06-02 1995-12-14 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
SK165197A3 (en) * 1995-06-07 1999-01-11 Astra Ab Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
GB9518864D0 (en) * 1995-09-14 1995-11-15 Cambridge Res & Innovation Oligonucleotides and their uses
GB9603314D0 (en) * 1996-02-16 1996-04-17 Biocine Spa Immunogenic detoxified mutant toxins
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua

Similar Documents

Publication Publication Date Title
Zhou et al. Poly-d, l-lactide–co-poly (ethylene glycol) microspheres as potential vaccine delivery systems
Esparza et al. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid
JP2003511420A5 (cg-RX-API-DMAC7.html)
Singh et al. Nanoparticles and microparticles as vaccine-delivery systems
JP4918188B2 (ja) サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
US6287604B1 (en) Biodegradable targetable microparticle delivery system
JP2963540B2 (ja) 薬剤移送用ポリマーミクロ粒子
AU2001294898B2 (en) Microparticle compositions and methods for the manufacture thereof
Singh et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice
Singh et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine
Lima et al. Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system
Lavelle et al. The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol
JP2001511148A (ja) 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用
JP2004509914A5 (cg-RX-API-DMAC7.html)
Singh et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2
JP2002521425A5 (cg-RX-API-DMAC7.html)
JP2016117774A (ja) リン脂質を含む免疫原性組成物
Vela Ramirez et al. Polyanhydride nanovaccines induce germinal center B cell formation and sustained serum antibody responses
JP2007308500A (ja) Gm−csfの放出の延長
JP2006520746A5 (cg-RX-API-DMAC7.html)
Singh et al. Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models
Khang et al. Preparation and characterization of Japanese encephalitis virus vaccine loaded poly (L‐lactide‐co‐glycolide) microspheres for oral immunization
Johansen et al. Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alkylated PLA/PLGAs
JPH08507088A (ja) 免疫応答の増強方法
McGee et al. The immunogenicity of a model protein entrapped in poly (lactide-co-glycolide) microparticles prepared by a novel phase separation technique